Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05587127
Other study ID # 2022P001765
Secondary ID K23DK131334-01
Status Recruiting
Phase N/A
First received
Last updated
Start date November 30, 2022
Est. completion date August 2026

Study information

Verified date February 2024
Source Massachusetts General Hospital
Contact Blythe Peterson, BS
Phone 617-643-7884
Email GIbehavioralresearch@mgh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss.


Description:

The purpose of this study is to conduct a randomized controlled trial (RCT) of a cognitive-behavioral treatment (CBT) compared to usual care as the control with adults with functional dyspepsia who also meet criteria for avoidant/restrictive food intake disorder (ARFID). Participants randomized into the CBT group will receive eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom while the usual care group will be allowed to continue with treatment they are already receiving at the time of randomization. Participants in the usual care group will be offered CBT after study participation. We will determine the feasibility and acceptability of the CBT and explore changes in clinical outcomes and preliminary mechanisms.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date August 2026
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Age at least 18 years at screening visit - Rome IV Functional Dyspepsia post-prandial distress type (with or without epigastric pain syndrome) - Negative upper endoscopy or upper radiographic GI series to rule out structural/organic cause for FD - Avoidant/Restrictive Food Intake Disorder (ARFID) diagnosis (by the Structured Clinical Interview for DSM-5; SCID-5 at Screening visit) - =5% weight loss from weight after functional dyspepsia symptom onset (at Screening visit) - Stable for outpatient care (based on the American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders) - No previous history of CBT for functional dyspepsia or ARFID - Computer/internet webcam access - Fluency in English - Stable dose for 30 days if on any medication Exclusion Criteria - Inability to provide informed consent - Presence of other conditions that could explain the patient's symptoms by chart: Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT) Active H.pylori infection (by CLO test or stool antigen test) Active inflammatory bowel disease Eosinophilic gastroenteritis or eosinophilic esophagitis Acute renal failure Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis Acute liver failure Any acute gastrointestinal process Any plausible structural or metabolic causes Heartburn as predominant symptom History of peptic ulcer - Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed) - History of gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection) - History of any serious medical condition (e.g., cancer) - Use of narcotic analgesics greater than three days per week - Current pregnancy or breastfeeding within the last 8 weeks - Uncontrolled diabetes (indicated by HbA1c =7%) by chart - Intellectual disability by history - Current substance/alcohol use disorder within the past month - Current/history of psychosis (by Mini-International Neuropsychiatric Interview (MINI-Screen) - Current mania (by Mini-International Neuropsychiatric Interview (MINI-Screen) (defined as any manic episodes within the past 12 months) - Active suicidal ideation (by MINI-Screen) - Psychiatric disorder that would warrant independent attention (by Mini-International - Neuropsychiatric Interview (MINI-Screen)) - Current enteral or parenteral feeding - Plans to initiate another psychotherapy or pregnancy in the concurrent study period

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Behavioral Therapy
Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Massachusetts General Hospital National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Enrollment At the end of the study, we will calculate the percentage of participants who consent to initiate the study from the total who are offered. Throughout study completion, an average of 3 years
Primary Assessment completion At the end of the study, we will calculate the percentage of participants who complete all assessments in each CBT and usual care groups. Throughout study completion, an average of 3 years
Primary Retention At the end of the study, we will calculate the percentage of participants who complete at least 6 of the 8 CBT sessions. Throughout study completion, an average of 3 years
Primary Interventionist Fidelity ratings At the end of the study, we will calculate fidelity, which measures the percentage of sessions that 100% of the CBT content was delivered. Throughout study completion, an average of 3 years
Primary Client Satisfaction The Client Satisfaction Questionnaire (CSQ) is an 8 item self-report measure that assesses treatment satisfaction. Higher scores indicate greater treatment satisfaction. Week 12
Secondary Short Form Nepean Dyspepsia Inventory (SF-NDI) The Short Form Nepean Dyspepsia Inventory (SF-NDI) includes a 15 item symptoms checklist to assess functional dyspepsia symptom severity. It also includes 10 items scored on a 5-point Likert scale measuring functional dyspepsia-related quality of life; subscales include interference with daily activities, knowledge/control, tension, work/study, and eating/drinking. Weeks 0, 6, and 12
See also
  Status Clinical Trial Phase
Recruiting NCT06094062 - Smartphone App-assisted PPI N/A
Completed NCT03941288 - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Phase 2
Completed NCT04429802 - The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Withdrawn NCT02863822 - Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia. N/A
Recruiting NCT00978159 - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Phase 4
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Completed NCT00217347 - Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy N/A
Completed NCT00148603 - Montelukast in the Treatment of Duodenal Eosinophilia N/A
Terminated NCT00220844 - Tricyclic Antidepressants (TCAs) on Gastric Emptying N/A
Completed NCT00232102 - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Phase 3
Completed NCT00164996 - Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia Phase 3
Completed NCT00232037 - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Phase 3
Completed NCT00110968 - Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia Phase 3
Recruiting NCT05718960 - Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia N/A
Terminated NCT04247100 - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders N/A
Completed NCT05750641 - The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
Completed NCT03252743 - ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study. N/A
Completed NCT04697641 - Helicobacter Pylori Eradication in Functional Dyspepsia N/A
Recruiting NCT04918329 - Functional Digestive Disorders Observatory